Condition: Urothelial Carcinoma · Sponsor: Erasmus Medical Center
Patients with locally advanced or clinically node positive urothelial carcinoma treated with chemotherapy, will receive 3 cycles of avelumab, followed by radical surgery.
This description comes directly from the study's public registry record.
J L Boormans, MD PhD · 0031 10 7032612 · j.boormans@erasmusmc.nl
V C Rutten, MD · v.rutten@erasmusmc.nl
Always discuss trial participation with your own doctor first.
| Radboud UMC | Nijmegen, Gelderland, Netherlands | Recruiting |
| Jeroen Bosch ziekenhuis | 's-Hertogenbosch, North Brabant, Netherlands | Recruiting |
| Amphia ziekenhuis | Breda, North Brabant, Netherlands | Recruiting |
| Erasmus MC | Rotterdam, South Holland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05600127